BioSpace News Archive

Aclaris Therapeutics, Inc. announced positive preliminary topline results from its first in human Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in 50 subjects with moderate to severe atopic dermatitis .

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte’s current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D’Amour, PhD.

Promega GoTaq® Rapid Master Mix paired with Eppendorf Mastercycler® X50s thermal cycler is one of the fastest endpoint PCR solutions available

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7.

Onward Therapeutics and Institut du Cancer de Montpellier announced the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by ICM, Montpellier, France.

THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population respondingsuboptimally to anti-VEGF therapy

Polyphor AG announced that it will host a key opinion leader roundtable on Covid-19, the need for novel therapies for severe infections and the potential role of balixafortide, a selective CXCR4 antagonist, on Thursday, June 10, 2021 at 8am Eastern Time/2pm Central European Time.

Astellas Pharma Inc. announced the presentation of new data in acute myeloid leukemia at the European Hematology Association virtual congress, taking place June 9-17.

AB Science SA is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib.

According to the report, the global vascular closure devices market was valued at US$ 0.8 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.